Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China

Executive Summary

Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.

Advertisement

Related Content

Three-Decades Tenure But No Loyalty: Genentech Scientist Charged With Biosimilar Trade Secrets Theft
Three-Decades Tenure But No Loyalty: Genentech Scientist Charged With Biosimilar Trade Secrets Theft
Sanofi’s Keeney On Early-Stage Assets, 'Open Dialogue' With Asian Start-Ups
Amgen & Simcere Plot Long Run On Biosimilars In China
Amgen & Simcere Plot Long Run On Biosimilars In China
New $350m Site To Build Pfizer’s China Biosimilar Capacity
Lilly Builds On Innovent Biologics China Bet
Oncobiologics raises $31m for biosimilars; RaNA, Ra, SutroVax add VC cash
China's new biosimilars guideline: more flexibility, but stricter in parts
China's Zai Lab In-Licenses Two Sanofi Respiratory Drugs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097883

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel